Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1157-1168

  Zou, Changye Y ^a   Smith, Kerrington D ^a   Zhu, Quan Sheng ^a   Liu, Jun ^a   McCutcheon, Ian E ^a   Slopis, John M ^a   Meric Bernstam, Funda ^a   Peng, Zhenghong ^a   Bornmann, William G ^a   Mills, Gordon B ^a   Lazar, Alexander J ^a   Pollock, Raphael E ^a   Lev, Dina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NERVE SHEATH TUMOR; NEUROFIBROMA; PRIORITY JOURNAL; TISSUE MICROARRAY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; FURANS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MOLECULAR TARGETED THERAPY; NERVE SHEATH NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 66849131261     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1008     Document Type: Article

References (49)

1. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-2021
2. Collin C, Godbold J, Hajdu S, Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987;5:601-612 (Pubitemid 17062498)
3. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-314 (Pubitemid 34526349)
4. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006;107:1065-1074 (Pubitemid 44291156)
5. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42:351-360 (Pubitemid 28502782)
6. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005;102:8573-8578 (Pubitemid 40862777)
7. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005;65:2755-2760 (Pubitemid 40490077)
8. Johannessen CM, Johnson BW, Williams SM, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008;18:56-62.
9. Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 2008;7:1237-1245
10. Perry A, Roth KA, Banerjee R, Fuller CE, Gutmann DH. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 2001;159:57-61. (Pubitemid 33704192)
11. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-361 (Pubitemid 41080576)
12. Abraham RT. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 2002;111:9-12.
13. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734 (Pubitemid 44286004)
14. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058 (Pubitemid 41161231)
15. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-1940 (Pubitemid 46474636)
16. Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005;65:3336-3346 (Pubitemid 40524618)
17. Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 2003;17:449-454 (Pubitemid 36258759)
18. Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
19. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006;125:733-747
20. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349 (Pubitemid 43668732)
21. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-5850 (Pubitemid 46985018)
22. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-2591
23. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15:5256-5267 (Pubitemid 26336209)
24. Zhu QS, Ren W, Korchin B, et al. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45α. Cancer Res 2008;68:2895-2903
25. Holtkamp N, Malzer E, Zietsch J, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol 2008;10:946-957
26. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch 2002;440:610-615
27. Kawaguchi K, Oda Y, SaitoT , et al. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol 2005;36:357-363 (Pubitemid 40591805)
28. Kawaguchi K, Oda Y, SaitoT , et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 2006;19:106-114 (Pubitemid 43250985)
29. Kanazawa T, Taneike I, Akaishi R, et al. Aminoacids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes. J Biol Chem 2004;279:8452-8459 (Pubitemid 38294738)
30. Iwamaru A, Kondo Y, Iwado E, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007;26:1840-1851 (Pubitemid 46474638)
31. Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 2005;1:84-91.
32. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-676 (Pubitemid 129516338)
33. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 2002;62:4507-4513 (Pubitemid 34827315)
34. Ling BC, Wu J, Miller SJ, et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005;7:65-75. (Pubitemid 40126383)
35. Tabone-Eglinger S, Bahleda R, Cote JF, et al. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008;2008:849156.
36. Mantripragada KK, Spurlock G, Kluwe L, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 2008;14:1015-1024
37. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007-1018 (Pubitemid 47359144)
38. Wang X, Yue P, Chan CB, et al. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007;27:7405-7413 (Pubitemid 350033648)
39. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457-468 (Pubitemid 35284167)
40. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101
41. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168
42. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472-1487 (Pubitemid 34686329)
43. Larsson O, Li S, Issaenko OA, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 2007;67:6814-6824
44. Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008;22:1728-1736
45. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 2001;81:833-844 (Pubitemid 32553405)
46. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999;286:2172-2176 (Pubitemid 129516295)
47. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-894 (Pubitemid 29086744)
48. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587-6597 (Pubitemid 35177037)
49. Aki T, Yamaguchi K, Fujimiya T, Mizukami Y. Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2. Oncogene 2003;22:8529-8535 (Pubitemid 37523905)